The mission of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the United States Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of the public health.
ACTTION is a multi-year, multi-phase initiative that is closely aligned with the FDA's Critical Path Initiative. This public-private partnership has been designed to streamline the discovery and development process for new analgesic, anesthetic, and addiction medications and to more generally accelerate the development of treatments with improved efficacy and safety.
The key objectives of ACTTION involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders — including, but not limited to, academia, the FDA and other government agencies, industry, professional organizations, patient advocacy groups, foundations, and philanthropic organizations — with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, for example, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency.
ACTTION is intended to have benefits that are international in scope. To represent the bridges that ACTTION is establishing among its diverse stakeholders, this website is illustrated with watermarks of two bridges that share the distinction of connecting different continents. Directly below is the First Bosphorus Bridge in Istanbul, Turkey, which connects Europe and Asia; on the Contact Us webpage is the Leifur Eiriksson Bridge in Iceland's Reykjanes peninsula, which spans a rift valley between the North American and European continental plates.
April 6, 2015: Acute Pain Taxonomy to be Developed with APS and AAPM
ACTTION is very pleased to announce the launch of a collaboration with the American Pain Society and the American Academy of Pain Medicine to develop diagnostic criteria for acute pain conditions. As with the ACTTION-APS chronic pain effort, the goal of this new initiative will be the development of a coordinated and evidence-based taxonomy. A comprehensive acute pain taxonomy is essential so that consistent and accurate diagnoses are used for clinical research and clinical trials, and also to facilitate comparisons across studies for systematic reviews and meta-analyses.
April 1, 2015: ACTTION Participates in FDA Workshop on Clinical Outcomes Assessment
Robert Dworkin, PhD, and Dennis Turk, PhD, ACTTION Director and Associate Director, were panelists at an FDA Public Workshop on "Clinical Outcomes Assessment Development and Implementation: Opportunities and Challenges." The workshop provided an opportunity for multiple stakeholders to discuss the FDA Clinical Outcomes Initiative, which includes the development of a compendium of clinical outcome assessments and other efforts to advance scientific standards and policy development.
March 20, 2015: AAPM Symposium Highlights ACTTION Activities
Daniel Carr, MD, ACTTION Board of Advisors Co-Chair, and John Markman, MD, ACTTION Executive Committee Co-Chair, were speakers in a symposium on "Contemporary Issues in Analgesic Development" that was held at the annual meeting of the American Academy of Pain Medicine. The symposium provided an overview of past and current progress in analgesic development, and emphasized the efforts of ACTTION to develop novel strategies to expedite the discovery and development of analgesic treatments with improved efficacy and safety.
March 13, 2015: ACTTION Poster Awarded Best of Category for Patient Safety
A poster presentation by Mark Williams, MBBS, and colleagues at the annual meeting of the International Anesthesia Research Society was selected to receive a Best of Category award as the best abstract submission in the Patient Safety category. The poster presented a systematic review of adverse event reporting in clinical trials of interventional pain treatments. The complete reference for the presentation is: Williams MR, Smith SM, Gilron I, Turk DC, Dworkin RH. Examining adverse event reporting in clinical trials of interventional pain treatments: An ACTTION systematic review. International Anesthesia Research Society annual meeting, Honolulu, March 23, 2015.